SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla gets 6 observations from USFDA for Goa plant

29 Aug 2022 Evaluate

Cipla has received 6 observations with some referencing to the observations made during the September 2019 inspection, for its Goa plant. There are no data integrity (DI) observations. The company will work closely with the USFDA and is committed to address these within the stipulated time.

The USFDA had inspected company's Goa plant during August 16-26, 2022. Earlier the USFDA had inspected the said facility in September 2019 and the issued warning letter in February 2020.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1234.00 -4.30 (-0.35%)
20-Apr-2026 12:08 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.50
Dr. Reddys Lab 1236.80
Cipla 1234.00
Zydus Lifesciences 938.50
Lupin 2323.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×